Navigation Links
Inverness Medical Innovations Announces Second Quarter 2008 Results
Date:7/29/2008

$(1.17) $0.25

Diluted $(1.17) (i) $0.24 (k)

Weighted average common shares -

basic 46,671 46,671

Weighted average common shares -

diluted 46,671 (i) 48,512 (k)

(a) In calculating net income or loss on an adjusted cash basis, the

Company excludes from net income or loss (i) certain non-cash charges,

including amortization expense and stock-based compensation expense, (ii)

non-recurring charges and income, and (iii) certain other charges and

income that have a significant positive or negative impact on results yet

do not occur on a consistent or regular basis in its business. In

determining whether a particular item meets one of these criteria,

management considers facts and circumstances that it believes are

relevant. Management believes that excluding such charges and income from

income or loss allows investors and management to evaluate and compare the

Company's operating results from continuing operations from period to

period in a meaningful and consistent manner. Due to the frequency of

their occurrence in its business, the Company does not adjust net income

or loss for the costs associated with litigation, including payments made

or received through settlements. It should be noted that "net income or

loss on an adjusted cash basis" is not a standard financial measurement

under accounting principles generally accepted in the United States of

America ("GAAP") and should not be considered as an alternative to net

income or loss or cash flow from operating activities, as a measure of

liquidity or as an indicator of operating performance or any measure of

performance derived in accordance with GAAP.

(b) Amortizati
'/>"/>

SOURCE Inverness Medical Innovations, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Inverness Medical Innovations Agrees to Acquire Panbio Ltd.
2. Inverness - Chemogen Establish Exclusive License for TB Antibodies
3. Inverness Medical Innovations Announces Proposed Public Offering of Common Stock
4. Inverness Medical Innovations Agrees to Acquire ParadigmHealth
5. Inverness Medical Innovations Acquires ParadigmHealth
6. Inverness Medical Innovations to Participate at JP Morgan Healthcare Conference on January 8, 2008
7. Inverness Medical Innovations to Participate at 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference on February 5, 2008
8. Correction to Press Release Dated January 31, 2008: Inverness Medical Innovations to Participate at 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference on February 5, 2008
9. Inverness Medical Innovations Completes Acquisition of BBI Holdings Plc
10. Inverness Medical Innovations Announces Fourth Quarter 2007 Results
11. Inverness Medical Innovations to Participate at Bank of America 2008 Smid Cap Conference on March 26, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/25/2015)... , March 25, 2015  S&P Capital IQ ... Factual Stock Report coverage on Abattis Bioceuticals Corp ... CSE: ATT): is a specialty biotechnology company with ... licensing and marketing proprietary ingredients, bio-similar compounds, patented ... North America . The company ...
(Date:3/25/2015)... CAMBRIDGE, Mass. and REYKJAVIK, ... which provides comprehensive capabilities for using the genome to create ... their publication of the largest studies of whole-genome data yet ... in Nature Genetics – are built ... variation, authored by a team of deCODE scientists led by ...
(Date:3/25/2015)... 25, 2015 Data from Evidence ... of Action in Neuromuscular Diseases , South ... Incorporated (Nasdaq: CYTK) announced the publication of a ... activator tirasemtiv in the journal Neurotherapeutics. This ... of Effect” or hypothesis-generating clinical trial which evaluated ...
(Date:3/25/2015)... and the HAGUE, Netherlands ... two-year results of LES Stimulation therapy for chronic gastro-esophageal ... journal Surgery [ Surgery . 2015; ... of its minimally-invasive therapy. The study ... duration of 11 years and taking prescribed daily proton ...
Breaking Biology Technology:S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 5Landmark deCODE Studies Demonstrate the Power of Truly Big Genomics for Improving Medicine Worldwide 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 3Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 4Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 5Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 6EndoStim LES Stimulation therapy demonstrates long term safety and efficacy results in treating reflux patients 2EndoStim LES Stimulation therapy demonstrates long term safety and efficacy results in treating reflux patients 3
... Multiporator / Electroporator 2510 , , , , , , , ... Protocol No. 4308 915.509 12/2001 , , , ... , , Microorganism , ... Cell type , Bacteria, gram positive, , ...
... , , Multiporator / Electroporator 2510 , , , , , , ... Transformation Protocol , Protocol No. 4308 915.506 12/2001 , , ... , , Microorganism , ... Cell type , Bacteria, gram negative, ...
... , , , , , , Multiporator , , , ... Transfection Protocol , Protocol No. 4308 915.042 11/2001 , ... , , , , ... , Transfection with , Plasmid pEGFP-N1 (in bidistilled ...
Cached Biology Technology:Clostridium botulinum 2Borrelia burgdorferi 2B16 2
(Date:3/20/2015)... , Mar. 19, 2015 Research and Markets ... "Iris Biometrics - Global Strategic Business Report" report to ... for Iris Biometrics in US$ Thousands. The report provides separate ... Japan , Europe , ... , and Latin America . ...
(Date:3/17/2015)... Emotient, the leader in facial expression ... availability of Emotient Analytics , the world,s ... facial expressions. The system analyzes videos of people ... services. It delivers audience response metrics - such ... derived from facial evidence of emotional states. Consumer ...
(Date:3/12/2015)... , March 12, 2015 The mascots of ... Children,s Hospital, part of Wake Forest Baptist Medical Center. ... for the 2015 ACC Men,s Basketball Tournament. Young patients ... them and getting their autographs. Brenner Children,s ... It is the only children,s hospital in northwest ...
Breaking Biology News(10 mins):Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 2New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 4
... - One of the most common house ant species might ... spaces in a forest, but the ants have found ways ... Grzegorz Buczkowski, a Purdue University research assistant professor of entomology, ... complex as they move from forest to city and act ...
... -- Amphibiansfrogs, toads, salamanders, and newtsare disappearing worldwide, but ... be stable. This region is home to the largest ... species reside here), and scientists want to understand what ... research published in the March 29, 2010 issue of ...
... for a gene to create a protein, the gene,s DNA ... These RNA molecules are the instruction manuals that show the ... a protein. A few years ago, scientists studying bacterial cells ... can bind to. In doing so, they induce the RNA ...
Cached Biology News:Common house ants form supercolonies, prosper in urban settings 2Young salamanders' movement over land helps stabilize populations 2Young salamanders' movement over land helps stabilize populations 3Genes under control 2
... Automated Spot Picking,A modified digital scanner serves ... three of the five standard rack positions ... to 4 micro well plates on the ... selection of single spots by mouse-click on ...
... Features hardwall acrylic panels ... frame to form a free-standing ... to Class 10/ISO 3. Optional ... and ionizers are configured to ...
... Phosphate Sensor is a highly sensitive ... This product is a purified form of ... the fluorophore MDCC, which is sensitive to ... inorganic phosphate by Phosphate Sensor is rapid ...
Sigmas E-TOXATE (Limulus Amebocyte Lysate) test kits are intended for the detection and semiquantitation,of endotoxins for research purposes....
Biology Products: